You're right that the methods are simoly not good enough. Further a large fraction of pharma research has shifted to biologics which doesn't depend on structure

You're right that the methods are simoly not good enough. Further a large fraction of pharma research has shifted to biologics which doesn't depend on structure prediction for new compounds, etc but they only need the hi res structure of their target protein (which more often than not is already done) to go on and generate the antibodies and make sure they direct the desired motif on the target.